Novavax's Dr. Gale Smith to Chair Scientific Congress
The three-day conference, which begins February 5, focuses on process development, high throughput screening and production issues involving vaccines and therapeutic products derived from insect cells. Dr. Smith is the co-inventor of the insect cell-baculovirus expression technology, which is widely used in the discovery and manufacture of recombinant DNA products including human vaccines.
Novavax is developing virus-like particle (VLP) vaccines for pandemic and seasonal influenza, HIV/AIDS, and other important diseases using the insect cell-baculovirus expression system.
Dr. Smith will deliver a presentation entitled "The Baculovirus Expression System as a New Platform for Virus-Like Particle Vaccines" at 8:30 a.m. PST February 5.
Novavax Inc. is committed to leading the global fight against infectious disease by creating novel, highly potent vaccines that are safer and more effective than current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral diseases. Novavax's particulate vaccines closely match disease-causing viruses while lacking the genetic material to cause disease, which provides potential for greater immune protection at lower doses than current vaccines. With an exclusive portable manufacturing system that allows for rapid mass-production of vaccines, Novavax is uniquely positioned to meet global public health needs.
SOURCE Novavax Inc.
Mariann Caprino, +1-240-268-2029